Cong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cong Liu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Chunlin Hu
Department of Emergency Medicine, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China
3 shared publications - Hongyan Wei
Department of Emergency Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
3 shared publications - Zhang
Department of Emergency Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publications - Bo Li
Department of Emergency Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
2 shared publications - Chuyue Wang
Department of Emergency Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
2 shared publications - Dawang Zhou
Department of Emergency Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
2 shared publications
Latest Publications
- Open Access
- 18 January 2026
- Published by SAGE Publications in Sage Open Medicine
- Vol. 14
Research progress on beta-blockers in the treatment of sepsis-induced cardiomyopathy: A mini review
Sepsis-induced cardiomyopathy (SCM), a frequent complication of septic shock with mortality exceeding 40%, arises from catecholamine-driven cardiotoxicity, sympathetic hyperactivity, and inflammation-mediated biventricular dysfunction. Short-acting β₁-blockers (esmolol, landiolol) offer a targeted therapeutic approach by reducing heart rate (target: 80–95 bpm), myocardial oxygen demand, and proinflammatory cytokines while improving diastolic perfusion—leveraging ultra-short half-lives (t₁/₂ = 4–9 min) for rapid reversibility during instability. Clinical evidence remains divergent: a landmark single-center RCT demonstrated significant 28-day mortality reduction (49.4% vs 80.5%; p < 0.001), improved hemodynamics, and reduced vasopressor requirements in hemodynamically stabilized patients, whereas premature termination of a multicenter trial revealed harm (increased vasopressor needs, mortality trend) when initiated during persistent hypoperfusion (lactate > 2 mmol/L). Current limitations include heterogeneous trial designs, small samples, and undefined benefiting phenotypes. Thus, cautious short-acting β-blockade is supported only for selected SCM patients with hemodynamic stability (MAP ⩾65 mmHg, normalized lactate, LVEF >35%), necessitating future precision trials with AI phenotyping to guide mechanism-targeted application.
- 18 January 2026
- Published by SAGE Publications in Sage Open Medicine
- Vol. 14
Open AccessResearch progress on beta-blockers in the treatment of sepsis-induced cardiomyopathy: A mini review
Sepsis-induced cardiomyopathy (SCM), a frequent complication of septic shock with mortality exceeding 40%, arises from catecholamine-driven cardiotoxicity, sympathetic hyperactivity, and inflammation-mediated biventricular dysfunction. Short-acting β₁-blockers (esmolol, landiolol) offer a targeted therapeutic approach by reducing heart rate (target: 80–95 bpm), myocardial oxygen demand, and proinflammatory cytokines while improving diastolic perfusion—leveraging ultra-short half-lives (t₁/₂ = 4–9 min) for rapid reversibility during instability. Clinical evidence remains divergent: a landmark single-center RCT demonstrated significant 28-day mortality reduction (49.4% vs 80.5%; p < 0.001), improved hemodynamics, and reduced vasopressor requirements in hemodynamically stabilized patients, whereas premature termination of a multicenter trial revealed harm (increased vasopressor needs, mortality trend) when initiated during persistent hypoperfusion (lactate > 2 mmol/L). Current limitations include heterogeneous trial designs, small samples, and undefined benefiting phenotypes. Thus, cautious short-acting β-blockade is supported only for selected SCM patients with hemodynamic stability (MAP ⩾65 mmHg, normalized lactate, LVEF >35%), necessitating future precision trials with AI phenotyping to guide mechanism-targeted application.
- Open Access
- 23 April 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 64 (5) , 454-465
Implications of Protein Posttranslational Modifications in Sepsis-Induced Acute Lung Injury and Acute Respiratory Distress Syndrome
Sepsis, a complex clinical syndrome, is characterized by the body’s excessive response to infection, which triggers systemic inflammation. The lungs are the most vulnerable organs in patients with this disease, leading to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) as common complications of sepsis. These complications significantly increase the risk of death for patients, profoundly affect their prognosis, and impose significant burdens on public health. Posttranslational modifications (PTMs) of proteins play a critical role in regulating protein solubility, activity, stability, and mediating protein-protein interactions. Any changes in homeostasis in the body can affect cellular function by altering PTMs, thereby promoting the development of ALI/ARDS. This review focuses on several validated PTMs and explores their specific mechanisms of action in sepsis-induced ALI/ARDS. We hope to provide novel insights for understanding the occurrence and development of the disease by summarizing existing research results and to provide a theoretical basis for the formulation of diagnosis and treatment strategies. Furthermore, future research directions will be discussed with the goal of advancing targeted therapies against PTMs to enhance clinical outcomes for patients suffering from sepsis.
- 23 April 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 64 (5) , 454-465
Open AccessImplications of Protein Posttranslational Modifications in Sepsis-Induced Acute Lung Injury and Acute Respiratory Distress Syndrome
Sepsis, a complex clinical syndrome, is characterized by the body’s excessive response to infection, which triggers systemic inflammation. The lungs are the most vulnerable organs in patients with this disease, leading to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) as common complications of sepsis. These complications significantly increase the risk of death for patients, profoundly affect their prognosis, and impose significant burdens on public health. Posttranslational modifications (PTMs) of proteins play a critical role in regulating protein solubility, activity, stability, and mediating protein-protein interactions. Any changes in homeostasis in the body can affect cellular function by altering PTMs, thereby promoting the development of ALI/ARDS. This review focuses on several validated PTMs and explores their specific mechanisms of action in sepsis-induced ALI/ARDS. We hope to provide novel insights for understanding the occurrence and development of the disease by summarizing existing research results and to provide a theoretical basis for the formulation of diagnosis and treatment strategies. Furthermore, future research directions will be discussed with the goal of advancing targeted therapies against PTMs to enhance clinical outcomes for patients suffering from sepsis.
- Open Access
- 30 December 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (3) , 1601-1604
Thyrotoxic periodic Paralysis With hypoxemia: A case report and a comprehensive review
- 30 December 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (3) , 1601-1604
Open AccessThyrotoxic periodic Paralysis With hypoxemia: A case report and a comprehensive review
- Open Access
- 20 June 2023
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (10) , 3129-3145
Targeted Activation of HNF4α by AMPK Inhibits Apoptosis and Ameliorates Neurological Injury Caused by Cardiac Arrest in Rats
Previous studies have shown that AMPK plays an important role in cerebral ischemia–reperfusion injury by participating in apoptosis, but the exact mechanism and target of action remains unclear. This study aimed to investigate the protective mechanism of AMPK activation on brain injury secondary to cardiac arrest. HE, Nills and TUNEL assays were used to evaluate neuronal damage and apoptosis. The relationships between AMPK, HNF4α and apoptotic genes were verified by ChIP-seq, dual-luciferase and WB assays. The results showed that AMPK improved the 7-day memory function of rats, and reduced neuronal cell injury and apoptosis in the hippocampal CA1 region after ROSC, while the use of HNF4α inhibitor weakened the protective effect of AMPK. Further research found that AMPK positively regulated the expression of HNF4α, and AMPK could promote the expression of Bcl-2 and inhibit the expression of Bax and Cleaved-Caspase 3. In vitro experiments showed that AMPK ameliorated neuronal injury by inhibiting apoptosis through the activation of HNF4α. Combined with ChIP-seq, JASPAR analysis and Dual-luciferase assay, the binding site of HNF4α to the upstream promoter of Bcl-2 was found. Taken together, AMPK attenuates brain injury after CA by activating HNF4α to target Bcl-2 to inhibit apoptosis.
- 20 June 2023
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (10) , 3129-3145
Open AccessTargeted Activation of HNF4α by AMPK Inhibits Apoptosis and Ameliorates Neurological Injury Caused by Cardiac Arrest in Rats
Previous studies have shown that AMPK plays an important role in cerebral ischemia–reperfusion injury by participating in apoptosis, but the exact mechanism and target of action remains unclear. This study aimed to investigate the protective mechanism of AMPK activation on brain injury secondary to cardiac arrest. HE, Nills and TUNEL assays were used to evaluate neuronal damage and apoptosis. The relationships between AMPK, HNF4α and apoptotic genes were verified by ChIP-seq, dual-luciferase and WB assays. The results showed that AMPK improved the 7-day memory function of rats, and reduced neuronal cell injury and apoptosis in the hippocampal CA1 region after ROSC, while the use of HNF4α inhibitor weakened the protective effect of AMPK. Further research found that AMPK positively regulated the expression of HNF4α, and AMPK could promote the expression of Bcl-2 and inhibit the expression of Bax and Cleaved-Caspase 3. In vitro experiments showed that AMPK ameliorated neuronal injury by inhibiting apoptosis through the activation of HNF4α. Combined with ChIP-seq, JASPAR analysis and Dual-luciferase assay, the binding site of HNF4α to the upstream promoter of Bcl-2 was found. Taken together, AMPK attenuates brain injury after CA by activating HNF4α to target Bcl-2 to inhibit apoptosis.
- Open Access
- 20 October 2022
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (5) , 2179-2202
Neuroprotective Effect of miR-483-5p Against Cardiac Arrest-Induced Mitochondrial Dysfunction Mediated Through the TNFSF8/AMPK/JNK Signaling Pathway
Substantial morbidity and mortality are associated with postcardiac arrest brain injury (PCABI). MicroRNAs(miRNAs) are essential regulators of neuronal metabolism processes and have been shown to contribute to alleviated neurological injury after cardiac arrest. In this study, we identified miRNAs related to the prognosis of patients with neurological dysfunction after cardiopulmonary resuscitation based on data obtained from the Gene Expression Omnibus (GEO) database. Then, we explored the effects of miR-483-5p on mitochondrial biogenesis, mitochondrial-dependent apoptosis, and oxidative stress levels after ischemia‒reperfusion injury in vitro and in vivo. MiR-483-5p was downregulated in PC12 cells and hippocampal samples compared with that in normal group cells and hippocampi. Overexpression of miR-483-5p increased the viability of PC12 cells after ischemia‒reperfusion injury and reduced the proportion of dead cells. A western blot analysis showed that miR-483-5p increased the protein expression of PCG-1, NRF1, and TFAM and reduced the protein expression of Bax and cleaved caspase 3, inhibiting the release of cytochrome c from mitochondria and alleviating oxidative stress injury by inhibiting the production of ROS and reducing MDA activity. We confirmed that miR-483-5p targeted TNFSF8 to regulate the AMPK/JNK pathway, thereby playing a neuroprotective role after cardiopulmonary resuscitation. Hence, this study provides further insights into strategies for inhibiting neurological impairment after cardiopulmonary resuscitation and suggests a potential therapeutic target for PCABI.
- 20 October 2022
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (5) , 2179-2202
Open AccessNeuroprotective Effect of miR-483-5p Against Cardiac Arrest-Induced Mitochondrial Dysfunction Mediated Through the TNFSF8/AMPK/JNK Signaling Pathway
Substantial morbidity and mortality are associated with postcardiac arrest brain injury (PCABI). MicroRNAs(miRNAs) are essential regulators of neuronal metabolism processes and have been shown to contribute to alleviated neurological injury after cardiac arrest. In this study, we identified miRNAs related to the prognosis of patients with neurological dysfunction after cardiopulmonary resuscitation based on data obtained from the Gene Expression Omnibus (GEO) database. Then, we explored the effects of miR-483-5p on mitochondrial biogenesis, mitochondrial-dependent apoptosis, and oxidative stress levels after ischemia‒reperfusion injury in vitro and in vivo. MiR-483-5p was downregulated in PC12 cells and hippocampal samples compared with that in normal group cells and hippocampi. Overexpression of miR-483-5p increased the viability of PC12 cells after ischemia‒reperfusion injury and reduced the proportion of dead cells. A western blot analysis showed that miR-483-5p increased the protein expression of PCG-1, NRF1, and TFAM and reduced the protein expression of Bax and cleaved caspase 3, inhibiting the release of cytochrome c from mitochondria and alleviating oxidative stress injury by inhibiting the production of ROS and reducing MDA activity. We confirmed that miR-483-5p targeted TNFSF8 to regulate the AMPK/JNK pathway, thereby playing a neuroprotective role after cardiopulmonary resuscitation. Hence, this study provides further insights into strategies for inhibiting neurological impairment after cardiopulmonary resuscitation and suggests a potential therapeutic target for PCABI.
- Open Access
- 15 July 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (7) , 928
Identification and Validation of Novel Potential Pathogenesis and Biomarkers to Predict the Neurological Outcome after Cardiac Arrest
Predicting neurological outcomes after cardiac arrest remains a major issue. This study aimed to identify novel biomarkers capable of predicting neurological prognosis after cardiac arrest. Expression profiles of GSE29540 and GSE92696 were downloaded from the Gene Expression Omnibus (GEO) database to obtain differentially expressed genes (DEGs) between high and low brain performance category (CPC) scoring subgroups. Weighted gene co-expression network analysis (WGCNA) was used to screen key gene modules and crossover genes in these datasets. The protein-protein interaction (PPI) network of crossover genes was constructed from the STRING database. Based on the PPI network, the most important hub genes were identified by the cytoHubba plugin of Cytoscape software. Eight hub genes (RPL27, EEF1B2, PFDN5, RBX1, PSMD14, HINT1, SNRPD2, and RPL26) were finally screened and validated, which were downregulated in the group with poor neurological prognosis. In addition, GSEA identified critical pathways associated with these genes. Finally, a Pearson correlation analysis showed that the mRNA expression of hub genes EEF1B2, PSMD14, RPFDN5, RBX1, and SNRPD2 were significantly and positively correlated with NDS scores in rats. Our work could provide comprehensive insights into understanding pathogenesis and potential new biomarkers for predicting neurological outcomes after cardiac arrest.
- 15 July 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (7) , 928
Open AccessIdentification and Validation of Novel Potential Pathogenesis and Biomarkers to Predict the Neurological Outcome after Cardiac Arrest
Predicting neurological outcomes after cardiac arrest remains a major issue. This study aimed to identify novel biomarkers capable of predicting neurological prognosis after cardiac arrest. Expression profiles of GSE29540 and GSE92696 were downloaded from the Gene Expression Omnibus (GEO) database to obtain differentially expressed genes (DEGs) between high and low brain performance category (CPC) scoring subgroups. Weighted gene co-expression network analysis (WGCNA) was used to screen key gene modules and crossover genes in these datasets. The protein-protein interaction (PPI) network of crossover genes was constructed from the STRING database. Based on the PPI network, the most important hub genes were identified by the cytoHubba plugin of Cytoscape software. Eight hub genes (RPL27, EEF1B2, PFDN5, RBX1, PSMD14, HINT1, SNRPD2, and RPL26) were finally screened and validated, which were downregulated in the group with poor neurological prognosis. In addition, GSEA identified critical pathways associated with these genes. Finally, a Pearson correlation analysis showed that the mRNA expression of hub genes EEF1B2, PSMD14, RPFDN5, RBX1, and SNRPD2 were significantly and positively correlated with NDS scores in rats. Our work could provide comprehensive insights into understanding pathogenesis and potential new biomarkers for predicting neurological outcomes after cardiac arrest.